

Curriculum Vitae

Personal information **Manuel Campos Toimil**

Work experience

1. Employer: University of Santiago de Compostela
 - Start date: 112010
 - End date:
 - Position: Profesor Titular de Universidad
 - Activities:
 - Country: Spain
2. Employer: University of Cambridge
 - Start date: 061999
 - End date: 022001
 - Position: Research Associate
 - Activities:
 - Country: United Kingdom
3. Employer: University of Santiago de Compostela
 - Start date: 102003
 - End date: 092008
 - Position: 'Ramón y Cajal' Researcher
 - Activities:
 - Country: Spain

Education and training

1. Subject: University of Santiago de Compostela
 - Start date:
 - End date: 071995
 - Qualification: PhD Pharmacy
 - Organisation: Pharmacology
 - Country: Spain

Additional information

Publications

JCR INDEXED MANUSCRIPTS

1. Moraña-Fernández S, Vázquez-Abuín X, Aragón-Herrera A, Anido-Varela L, García-Seara J, Otero-García O, Rodríguez-Penas D, Campos-Toimil M, Otero-Santiago M, Rodrigues A, Gonçalves A, Pereira Morais J, Alves IN, Sousa-Mendes C, Falcão-Pires I, González-Juanatey JR, Feijoo-Bandín S, Lago F. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction. *Biochem Pharmacol* 2024, 230 (1): 116571.
2. Giraldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Barreiro-de Acosta M, Lamas MJ, Zarra-Ferro I. Influencing factors on the persistence of infliximab and adalimumab treatment in Crohn's disease. *Authorea*. January 30, 2024.
3. Seoane N, Picos A, Moraña-Fernández S, Schmidt M, Dolga A, Campos-Toimil M[#], Viña D[#]. Effects of sodium nitroprusside on lipopolysaccharide-induced inflammation and disruption of blood brain barrier. *Cells* 2024, 13(10): 843. ()
4. Shevchuk O, Palii S, Pak A, Chantada N, Seoane N, Korda M, Campos-Toimil M, Álvarez E. Vessel-on-a-Chip: A Powerful Tool for Investigating Endothelial COVID-19 Fingerprints. *Cells*. 2023 May 2;12(9):1297.
5. Aragón-Herrera A, Moraña-Fernández S, Otero-Santiago M, Anido-Varela L, Campos-Toimil M, García-Seara J, Román A, Seijas J, García-Caballero L, Rodríguez J, Tarazón E, Roselló-Lletí E, Portolés M, Lage R, Gualillo O, González-Juanatey JR, Feijoo-Bandín S, Lago F. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats. *Biomedicine & Pharmacotherapy*. 2023, 161: 114535
6. Matos MJ, Uriarte E, Seoane N, Picos A, Gil-Longo J, Campos Toimil M. Synthesis and vasorelaxant activity of nitrate-coumarin derivatives. *ChemMedChem* 2022, 17(21): e202200476.
7. Carvalho GR, Braz DS, Gonçalves TCO, Aires R, Côco LZ, Guidoni M, Fronza M, Endringer DC, de Souza Junior AD, Campos Toimil M, Nogueira BV, Vasquez EC, Campagnaro BC, Pereira TMC. Development and evaluation of Virola oleifera formulation for cutaneous wound healing. *Antioxidants (Basel)* 2021, 11(9), 1647.
8. Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, Zarra-Ferro I, Gonzalez-Barcia M, Campos Toimil M, Mangas Sanjuan V, Mondelo Garcia C, Fernández-Ferreiro A. A review of population pharmacokinetics analyses of linezolid. *Clinical Pharmacokinetics* 2022.
9. Pereira TMC, Carvalho GR, Luaces-Regueira M, Bugallo-Casal A, Iglesias-Mejuto A, Nugteren L, Schmidt M, Viña D, Vasquez EC, Campos Toimil M. Nanomolar resveratrol reduces early alterations of pancreatitis and pancreatic cancer in pancreatic acinar cells. *Phytomedicine Plus*, 2022, 2: 100301.
10. Queiroz SAL, Ton AMM, Pereira TMC, Campagnaro BP, Martinelli L, Picos A, Campos-Toimil M^{*}, Vasquez EC. The gut microbiota-brain axis: a new frontier on neuropsychiatric disorders. *Frontiers in Psychiatry* 2022, 13: 872594.
11. Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Campos Toimil M, García-Caballero T, Barral L, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González-Juanatey JR, Feijoo-Bandín S, Lago F. The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male Zucker diabetic fatty rats towards a protective profile. *Frontiers Pharmacol* 2022, 13: 827033.

12. Pereira TMC, Côco LZ, Ton AMM, Meyrelles SS, Campos_Toimil M, Campagnaro BP, Vasquez EC. The emerging scenario of gut_brain axis: The therapeutic actions of the new actor kefir against neurodegenerative diseases. *Antioxidants (Basel)* 2021, 10(11): 1845.
13. Viña D, Seoane N, Vasquez EC, Campos_Toimil M. cAMP compartmentalization in cerebrovascular endothelial cells: new therapeutic opportunities in Alzheimer's disease. *Cells* 2021, 10(8): 1951.
14. Hashem_Dabaghian F, Ghods R, Shojaili A, Abdi L, Campos_Toimil M, Yousefsani B.S. Rhus coriaria L., a new candidate for controlling metabolic syndrome: A systematic review. *J Pharm Pharmacol* 2021, rgab120.
15. Rubiolo JA, Lence E, González_Bello C, Roel M, Gil_Longo J, Campos_Toimil M, TERNON E, Thomas OP, González_Cantalapiedra A, López_Alonso H, Vieytes MR, Botana LM. Crambescic C1 acts as a possible substrate of iNOS and eNOS increasing nitric oxide production and inducing in vivo hypotensive effect. *Frontiers Pharmacol* 2021., 12: 694639.
16. Francisco V, Ruiz_Fernández C, González_Rodríguez M, Cordero_Barreal A, Pino J, Viñuela JE, Lago F, Conde J, Gómez R, Carvalho GR, Pereira TMC, Campos_Toimil M, Gualillo O. Evaluation of Virola oleifera activity in musculoskeletal pathologies: inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib. *J Ethnopharmacol* 2021, 272: 113932.
17. Giraldez_Montero JM, Gonzalez_Lopez J, Campos_Toimil M, Lamas_Díaz MJ. Therapeutic drug monitoring of anti_tumour necrosis factor_α agents in inflammatory bowel disease: Limits and improvements. *Br J Clin Pharmacol* 2021, 87(5): 2216-2227.
18. González_Rodríguez M, Ruiz_Fernández C, Francisco V, Eldjoudi DA, Farrag AbdElHafez YR, Cordero_Barreal A, Pino J, Lago F, Campos_Toimil M, Rocha Carvalho GR, Melo Costa Pereira T, Gualillo O. Pharmacological extracts and molecules from Virola species: traditional uses, phytochemistry and biological activity. *Molecules* 2021, 26: 792.
19. Monteiro BL, Dias AT, Wanderkoke SC, Yokota R, Casarini DE, Leal MAS, Nogueira BV, Meyrelles SS, Campos_Toimil M, Campagnaro BP, Campos RR, Pereira TMC, Vasquez EC. Protective effects of kefir in the angiotensin II dependent hypertension. *J Funct Foods* 2020, 75: 104260.
20. Blanco_Dorado S, Belles Medall MD, Pascual_Marmaneu O, Campos_Toimil M, Otero_Espinar FJ, Rodríguez_Riego R, Rodríguez_Jato MT, Zarra_Ferro I, Lamas MJ, Fernández_Ferreiro A. Therapeutic drug monitoring of voriconazole: validation of a high performance liquid chromatography method and comparison with an ARK immunoassay. *Eur J of Hosp Pharm* 2020, 0: 1-6.
21. Blanco_Dorado S, Maroñas Amigo O, Latorre_Pellicer A, Rodríguez_Jato MT, López_Vizcaino A, Gómez Márquez A, Bardán García B, Belles Medall D, Barbeito Castiñeiras G, Pérez Del Molino Bernal ML, Campos_Toimil M, Otero Espinar F, Blanco Hortas A, Zarra Ferro I, Carracedo A, Lamas MJ, Fernández_Ferreiro A. A multicentre prospective study evaluating the impact of proton_pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. *Br J Clin Pharmacol* 2020, 86:1661-1666.
22. Blanco_Dorado S, Maroñas O, Latorre_Pellicer A, Rodríguez_Jato MT, López_Vizcaino A, Gómez Márquez A, Bardán García B, Belles Medall D, Barbeito Castiñeiras G, Pérez Del Molino Bernal ML, Campos_Toimil M, Otero Espinar F, Blanco Hortas A, Durán Piñeiro G, Zarra Ferro I, Carracedo A, Lamas MJ, Fernández_Ferreiro A. Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic_pharmacokinetic prospective multicenter study. *Pharmacotherapy* 2020, 40(1): 17-25.
23. Ton AMM, Campagnaro BP, Alves GA, Aires R, Côco LZ, Arpini CM, Oliveira TG, Campos_Toimil M, Meyrelles SS, Pereira TMC, Vasquez EC. Oxidative stress and dementia in Alzheimer's patients: effects of synbiotic supplementation. *Oxid Med Cell Longev* 2020, Article ID 2638703.
24. Leal MAS, Aires R, Pandolfi T, Marques VB, Campagnaro BP, Pereira TMC, Meyrelles SS, Campos_Toimil M, Vasquez EC. Sildenafil reduces endothelial dysfunction and structural damage in spontaneously hypertensive rats: Role of NO, NADPH and COX_1 pathways. *Vasc Pharmacol* 2020, 124: 106601.
25. Friques AGF, Santos FDN, Angeli DB, Silva FAC, Dias AT, Aires R, Leal MAS, Nogueira BV, Amorim FG, Campagnaro BP, Pereira TMC, Campos_Toimil M, Meyrelles SS, Vasquez EC. Bisphenol A contamination in infant rats: molecular, structural and physiological cardiovascular changes and the protective role of kefir. *J Nutr Biochem* 2020, 75: 108254.
26. Vasquez EC, Pereira TMC, Campos_Toimil M, Baldo MP, Peotta VA. Editorial: Gut microbiota, diet, and chronic diseases: the role played by oxidative stress. *Oxid Med Cell Longev* 2019, Article ID 7092032.
27. Aragón_Herrera A, Feijóo_Bandín S, Otero Santiago M, Barral L, Campos_Toimil M, Gil_Longo J, Pereira TMC, García_Caballero T, Rodríguez_Segade S, Rodríguez J, Tarazón E, Roselló_Lleti E, Portolés M, Gualillo O, González_Juanatey JR, Lago F. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. *Biochem Pharmacol* 2019, 170: 113677.
28. Chisté LA, Pereira BP, Porto ML, de Oliveira JP, Monteiro de Assis ALE, Nogueira BV, Meyrelles SS, Uggere de Andrade T, Campos_Toimil M, Vasquez EC, Campagnaro BP, Pereira TMC. Worsening of oxidative stress, DNA damage and atherosclerotic lesions in aged LDLr_/_ mice after consumption of guarana soft drinks. *Oxid Med Cell Longev* 2019, Article ID 9042526.
29. Vasquez EC, Pereira TMC, Peotta VA, Baldo MP, Campos_Toimil M. Probiotics as beneficial dietary supplements to prevent and treat cardiovascular diseases: uncovering their impact on oxidative stress. *Oxid Med Cell Longev* 2019, Article ID 3086270.
30. Blanco_Dorado S, Cea_Arestin C, González_Carballo A, Latorre_Pellicer A, Maroñas Amigo O, Barbeito Castiñeiras G, Pérez del Molino Bernal ML, Campos_Toimil M, Fernández_Ferreiro A, Lamas MJ. An observational study of the efficacy and safety of voriconazole in a real_life clinical setting. *J Chemother* 2018, 22: 1-9 (on line); *J Chemother* 2019, 31(1): 49-57 (printed).
31. Luaces_Regueira M, Castiñeira_Alvarinho M, Castro Manzanares M, Campos_Toimil M*; Domínguez_Muñoz JE* (*equal contribution). Pathophysiological events associated with pancreatitis in response to tobacco: an in vitro comparative study with ethanol in primary acinar cell culture. *Pancreas* 2018, 47(10): 1304-1311.
32. Dias AT, Leal MAS, Zanardo TC, Alves GM, Porto ML, Nogueira BV, Gava AL, Campagnaro BP, Pereira TMC, Meyrelles SS, Campos_Toimil M, Vasquez EC. Beneficial morphofunctional changes promoted by sildenafil in resistance vessels in the angiotensin II_induced hypertension model. *Curr Pharm Biotechnol* 2018, 19: 483-494.
33. Pimenta FS, Luaces_Regueira M, Ton AMM, Campagnaro BP, Campos_Toimil M, Pereira TMC, Vasquez EC. Mechanisms of action of kefir in chronic cardiovascular and metabolic diseases. *Cell Physiol Biochem* 2018, 48: 1901-1914.
34. Leal MAS, Dias AT, Porto ML, Brun BF, Gava AL, Meyrelles SS, Gil_Longo J, Campos_Toimil M, Pereira TMC, Vasquez EC. Sildenafil (Viagra®) prevents the Cox_1/TXA2 pathway mediated vascular hypercontractility in apoE_/_ mice. *Cell Physiol Biochem* 2017, 44: 1796-1809.
35. García_Morales V, Luaces_Regueira M, Campos_Toimil M. The cAMP effectors PKA and Epac activate endothelial NO synthase through PI3K/Akt pathway in human endothelial cells. *Biochem Pharmacol* 2017, 145: 94-101.
36. Munín J, Quezada E, Campos_Toimil M, Cano E, Uriarte E, Viña D. Synthesis and vasorelaxant and antiplatelet activities of a new series of (4-Benzylphthalazin_1_ylamino)alcohol derivatives. *Med Chem Res* 2017, 26(8): 1682-1688.
37. García_Morales V, Friedrich J, Jorna LM, Campos_Toimil M, Hammes HP, Schmidt M, Krenning G. The microRNA_7 mediated reduction in EPAC_1 contributes to vascular endothelial permeability and eNOS uncoupling in murine experimental retinopathy. *Acta Diabetol* 2017, 54(6): 581-591.
38. Cuiñas A, García_Morales V, Viña D, Gil_Longo J, Campos_Toimil M. Activation of PKA and Epac proteins by cyclic AMP depletes intracellular calcium stores and reduces calcium availability for vasoconstriction. *Life Sci* 2016, 155: 102-109.
39. Segade M, Bermejo R, Silva A, Paiva_Martins F, Gil_Longo J, Campos_Toimil M. Involvement of endothelium in the vasorelaxant effects of 3,4_DHPEA_EA and 3,4_DHPEA_EDA, two major functional bioactives in olive oil. *J Func Foods* 2016, 23: 637-646.

40. Munín J, Quezada E, Cuiñas A, Campos_Toimil M, Uriarte E, Santana L, Viña D. Synthesis, biological evaluation and structure_activity relationships of new phthalazinedione derivatives with vasorelaxant activity. *Eur J Med Chem* 2014, 82: 407_417.
41. García_Morales V, Cuiñas A, Elíes J, Campos_Toimil M. PKA and Epac activation mediates cAMP_induced vasorelaxation by increasing endothelial NO production. *Vasc Pharmacol* 2014, 60(3): 95_101.
42. Elíes J, Cuiñas A, MacDougall DA, Leiro J, Campos_Toimil M. Trans_resveratrol down_regulates caveolin_1, up_regulates endothelial NO synthase and reduces their interaction in vascular smooth muscle and endothelial cells. *Food Biosci* 2013, 1: 31_38.
43. Cuiñas A, Elíes J, Orallo F, Campos_Toimil M. Cyclic AMP relaxation of rat aortic smooth muscle is mediated in part by decrease of depletion of intracellular Ca2+ stores and inhibition of capacitative calcium entry. *Vasc Pharmacol* 2013, 58(1_2): 98_104.
44. Elíes J, Cuiñas A, García_Morales V, Orallo F, Campos_Toimil M. Trans_resveratrol simultaneously increases cytoplasmic Ca2+ levels and nitric oxide release in human endothelial cells. *Mol Nutr Food Res* 2011, 55(8): 1237_1248.
45. Campos_Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C. Short_term or long_term treatments with a phosphodiesterase_4 (PDE4) inhibitor result in opposing agonist_induced Ca2+ responses in endothelial cells. *Br J Pharmacol* 2008, 154(1): 82_92.
46. Campos_Toimil M, Elíes J, Álvarez E, Verde I, Orallo F. Effects of trans_ and cis_resveratrol on Ca2+ handling in A7r5 vascular myocytes. *Eur J Pharmacol* 2007, 577(1_3): 91_99.
47. Pickett JA, Campos_Toimil M, Thomas P, Edwardson JM. Identification of SNAREs that mediate zymogen granule exocytosis. *Biochem Biophys Res Commun* 2007, 359(3): 599_603.
48. Campos_Toimil M, Orallo F. Effects of ()_epigallocatechin_3_gallate in Ca2+_permeable non_selective cation channels and voltage_operated Ca2+ channels in vascular smooth muscle cells. *Life Sci* 2007, 80(23): 2147_2153.
49. Álvarez E, Campos_Toimil M, Justiniano_Basaran H, Lugnier C, Orallo F. Study of the mechanisms involved in the vasorelaxation induced by ()_epigallocatechin_3_gallate in rat aorta. *Br J Pharmacol* 2006, 147(3): 269_280.
50. Thomas P, Bagrij T, Campos_Toimil M, Edwardson JM. Mitochondria play a critical role in shaping the exocytotic response of rat pancreatic acinar cells. *Cell Calcium* 2006, 39(1): 57_63.
51. Campos_Toimil M, Elíes J, Orallo F. Trans_ and cis_resveratrol increase cytoplasmic calcium levels in A7r5 vascular smooth muscle cells. *Mol Nutr Food Res* 2005, 49(5): 396_404.
52. Álvarez_Castro E, Campos_Toimil M, Orallo F. ()_Epigallocatechin_3_gallate induces contraction of rat aorta by a calcium influx_dependent mechanism. *Naunyn Schmiedeberg's Arch Pharmacol* 2004, 369(5): 496_506.
53. Campos_Toimil M, Bagrij T, Edwardson JM, Thomas P. Two modes of secretion in pancreatic acinar cells: involvement of phosphatidylinositol_3_kinase and regulation by capacitative Ca2+ entry. *Current Biology* 2002, 12(3): 211_215.
54. Campos_Toimil M, Orallo F, Santana L, Uriarte E. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. *Bioorg Med Chem Lett* 2002, 12(5): 783_786.
55. Campos_Toimil M, Edwardson JM, Thomas P. Acetylcholine_induced zymogen granule exocytosis: comparison between acini and single pancreatic acinar cells. *Pancreas* 2002, 24(2): 179_183.
56. Orallo F, Rosa E, García_Ferreiro T, Campos_Toimil M, Cadavid MI, Loza MI. Cardiovascular effects of ketanserin on normotensive rats in vivo and in vitro. *Gen Pharmacol_Vasc Syst* 2000, 35(2): 95_105.
57. Campos_Toimil M, Edwardson JM, Thomas P. Real_time studies of zymogen granule exocytosis in intact rat pancreatic acinar cells. *J Physiol_London* 2000, 528(2): 317_326.
58. Campos_Toimil M, Lugnier C, Droy_Lefaux MT, Takeda K. Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist_induced Ca2+ rises in internal calcium in human endothelial cells. *Arterioscler Thromb Vasc Biol* 2000, 20(9): E34_E40.
59. Arranz E, Díaz JA, Vega S, Campos_Toimil M, Orallo F, Cardelús I, Llenas I, Fernández AG. Synthesis and pharmacological evaluation of 2,3_dihydro_3_oxo_4H_thieno[3,4_e][1,2,4] thiadiazine 1,1_dioxides as voltage_dependent calcium channel blockers. *Eur J Med Chem* 2000, 35(7_8): 751_759.
60. Scherberich A, Campos_Toimil M, Rondé P, Takeda K, Beretz A. Migration of human vascular smooth muscle cells involves serum_dependent repeated cytosolic calcium transients. *J Cell Sci* 2000, 113(4): 653_662.
61. Campos_Toimil M, Estévez I, Raviña E, Orallo F. Pyridazine derivatives XIV. Study of the vasorelaxant action of 6_aryl_5_piperidino_3_hydrazinopyridazines in isolated rat thoracic aorta: comparison with hydralazine. *Gen Pharmacol* 1998, 30(2): 201_207.
62. Orallo F, Alzueta AF, Campos_Toimil M, Calleja JM. Study of the in vivo and in vitro cardiovascular effects of (+)_glucine and N_carbethoxysecoglucine in rats. *Br J Pharmacol* 1995, 114(7): 1419_1427.
63. Campos_Toimil M, Orallo F, Gil_Longo J, Verde I, Loza I, Fernández_Alzueta A. Pharmacological study of several effects of hydralazine in the bisected rat vas deferens. *Eur J Pharmacol* 1994, 251(1): 83_90.
64. Moina MJ, Bardan B, Campos_Toimil M, Alzueta AF, Gil_Longo J, Orallo F. Effects of hydralazine on contractile responses to lapha1_ and alpha2_adrenoceptor agonists in isolated rubbed rat aorta. *Gen Pharmacol* 1994, 25(1): 165_172.
65. Orallo F, Alzueta AF, Loza MI, Vivas N, Badía A, Campos M, Honrubia MA., Cadavid MI. Study of the mechanism of the relaxant action of (+)_glucine in rat vas deferens. *Br J Pharmacol* 1993, 110(3): 943_948.
66. Orallo F, Fontenla JA, Loza MI, Campos M, Calleja JM. Effect of urethane on hydralazine_induced tachycardia in rats. *Gen Pharmacol* 1992, 23(6):1143_1147.
67. Gil_Longo J, Orallo F, Verde I, Campos M, Calleja JM. Role of the endothelial system in BAY K 8644 enantiomer and nifedipine vasomodulator action in rat aorta. *Eur J Pharmacol* 1992, 221(1): 1_8.
68. Orallo F, Verde I, Loza MI, Alzueta AF, Campos M, Freire_Garabal M. Effects of platelet activating factor on contractions and 45Ca influx induced by noradrenaline and potassium in rat rubbed and intact aorta. Comparison with its hypotensive effect in anaesthetized normotensive rats. *J Pharm Pharmacol* 1992, 44(4): 344_348.

INTERNATIONAL BOOK CHAPTERS

1. Elíes J, Yáñez M, Pereira TMC, Gil_Longo J, MacDougall DA, Campos_Toimil M. An update to calcium binding proteins. En: *Calcium Signaling*. Second Edition. Vol.1 (ISBN: 978_3_030_12457_1). Islam, S., ed. Springer Dordrecht, Heidelberg, Nueva York, Londres, pp: 183_213. (*Adv Exp Med Biol* 2020, 1131: 183_213. Índice de Impacto JCR: 2.450, Q2).
2. Yáñez M, Gil_Longo J, Campos_Toimil M. Calcium binding proteins. En: *Calcium Signaling* (ISBN: 978_94_007_2888_2). Islam S, ed. Springer Dordrecht, Heidelberg, Nueva York, Londres, 2012, pp: 461_482. (*Adv Exp Med Biol*. 2012, 740: 461_82. JCR: 1,825, Q2).
3. Campos_Toimil M, Elíes J, Orallo F. Cardiovascular effects of trans_ and cis_resveratrol. En: *Recent Progress in Medicinal Plants Vol. 21: Phytopharmacology and Therapeutic Values III*. ISBN: 1_9336991_1_6. Singh VK, Govil JN, eds. Studium Press LLC, USA, 2008, pp: 263_294.

NON_JCR INDEXED MANUSCRIPTS

1. Montáns_García R, Gómez_Besteiro MI, Campos_Toimil M, Balboa_Barreiro V. Listado de medicamentos a evitar en atención primaria y su aplicación en pacientes polimedicados. *Galicia Clínica* 2022, 83(1): 6-11.
2. Affonso HO, Andreão FL, Porto ML, Meyrelles SS, Vasquez EC, Baldo MP, Campos_Toimil M, Campagnaro BP, Pereira TMC. Nonconventional and conventional biomarkers evaluated in gold medalists beach volleyball players during the 2015 and 2016 seasons (pre_olympic and olympic years). *J Phys Edu Sport (JPES)* 2018, 18(3): 1779_1784.
3. Vasquez EC, Meyrelles SS, Gava AL, Campagnaro BP, Gil_Longo J, Campos_Toimil M, Pereira TMC. Beneficial effects of the synbiotic kefir on the neural control of cardiovascular function. *J. Food Microbiol*

- 2018, 2(S1): 25_33.
4. Luaces_Regueira M, Pereira TMC, Campos_Toimil M. New insights on the effects of prebiotics, probiotics and synbiotics in the gastrointestinal diseases and cancer. *J Food Microbiol* 2018, 2(S1): 19_22.
 5. Campos_Toimil M, Salgado F. El genoma, patrimonio de la humanidad. *Eureka!* (supl. científico Diario de Pontevedra) 21/11/2001: p3.
 6. Campos_Toimil M. A incidencia das alerxias. *Eureka!* (supl. científico Diario de Pontevedra) 31/10/2001: p6.
 7. Campos_Toimil M. O uso do cannabis con fins terapéuticos. *Eureka!* (supl. científico Diario de Pontevedra) 05/06/2001: p9.
 8. Campos_Toimil M. Chimpacés e humanos: onde está a diferenza? *Eureka!* (supl. científico Diario de Pontevedra) 09/05/2001: p36.
 9. Campos_Toimil M, Luginier C, Takeda K. Inhibition of agonist-induced rises in internal calcium in human endothelial cells by Ginkgo biloba extract (EGb 761) and rolipram. *Rev Fed Argent Cardiol* 2000, 29(3): 361_365.
 10. Campos_Toimil, M. O extracto de Ginkgo biloba, un remedio milenario na medicina do século XXI. *Rev Gal Ensino* 1999, 25: 181_190.
 11. Campos_Toimil, M. Aplicaciones terapéuticas del EGb 761, extracto de Ginkgo biloba. *OFFARM* 1998, 17(6): 74_80.
 12. Campos_Toimil M. Amlodipino: un nuevo antagonista del calcio con acción prolongada de comienzo gradual. *OFFARM* 1996, 15(11): 61_66.
 13. Campos M, Orallo F. La hidralazina: 50 años de investigación farmacológica II. *Rev OFIL* 1996, 6(3): 189_198.
 14. Campos M, Orallo F. La hidralazina: 50 años de investigación farmacológica I. *Rev OFIL* 1996, 6(2): 115_124.
 15. Campos M, Loza I, Fernández_Alzueta A, Orallo F, Longo J, Calleja JM. Actividad antisero-tonínica de la glauquina en aorta sin endotelio y en conducto deferente aislados de rata. *Ars Pharm* 1992, 33(1_4): 578_583.
 16. Loza I, Honrubia M, Fernández_Alzueta A, Campos M, Orallo F, Cadavid M, Gato A. Estudio de la actividad farmacológica de la glauquina en fundus de estómago aislado de rata. *Ars Pharm* 1992, 33(1_4): 584_589.
 17. Verde I, Orallo F, Gil_Longo J, Campos M. Efectos del endotelio sobre las contracciones inducidas por noradrenalina y K⁺ en las aortas de rata genéticamente hipertensa y rata normotensa. *Ars Pharm* 1992, 33(1_4): 641_646.
 18. Fernández_Alzueta A, Loza I, Orallo F, Campos M, Cadavid M. Acciones farmacológicas de la glauquina y la nantenina en aurículas aisladas de rata. *Ars Pharm* 1992, 33(1_4): 567_571.
 19. Verde I, Loza M, Gil_Longo J, Campos M, Orallo F, Calleja JM. Modulación por el endotelio de las contracciones inducidas por distintos agonistas alfa_adrenérgicos en la aorta de rata. *Pharm. Med.* 1990, 19: 459_464.

Projects

1. Consolidación y estructuración 2023 Grupos de Referencia Competitiva (GRC) GI-1682. Fisiología y Farmacología de las Enfermedades Crónicas - FIFAEC. Consellería de Educación, Universidade e Formación Profesional. Xunta de Galicia. RED431C 2023/22. 01/01/2023 a 20/11/2026. 280.000,00 €.
2. Efectos biológicos del kéfir en enfermedades dependientes del estrés oxidativo. Un análisis translacional. (Espírito Santo, Brasil). Entidad financiadora: FAPES (Fundação de Apoio à Pesquisa do Espírito Santo) Brasil. Referencia: TO #1042/2022 - Processo #2022-DCJS7. 01/12/2022-30/11/2025. 40.000 €.
3. Stimulation of NO/cGMP and cAMP pathways in the blood-brain barrier: a new therapeutic strategy in Alzheimer's disease (CYCLICBBB). Agencia Estatal de Investigación. Ministerio de Ciencia e Innovación (Spain). Reference: PID2020_119178GB_I00. 01/09/2021_31/08/2024. 84.700,00 €.
4. New biotechnological procedures in the treatment of chronic cardiovascular diseases and neurodegenerative cerebrovascular diseases. Support Program for Nuclei of Excellence (PRONEX), Fundación de Amparo a la Investigación e Innovación de Espírito Santo (FAPES), Brazil. Reference: CNPq/FAPES Nº 24/2018. 01/02/2019_31_01/2022. 373.460,00 BRL (~79.982,00 €).
5. Expertos universitarios para la prestación de servicios técnicos en el proceso de certificación en proyectos de I+D+I. DNV GL Business Assurance España SLU. Reference: 2015_CE104. 26/06/2015_25/06/2021. 12.350,00 €.
6. General research grants. Mode 1. GI_1683. Universidad de Santiago de Compostela. Reference: 2018PU068. 12/06/2018_31/12/2018. 5.000,00 €.
7. Interrelation between Ca²⁺ and cAMP signaling pathways in human endothelial cells cultured under static and flow conditions. Physiological implications. Subdirección General de Proyectos de Investigación. Ministerio de Ciencia e Innovación. Reference: SAF2010_22051. 01/01/2011_31/12/2011. 24.200,00 €.
8. Interaction between intracellular levels of cyclic AMP and Ca²⁺ in vascular cells. Implication in the regulation of vascular contractility. Dirección Xeral de I+D. Xunta de Galicia. Reference: INCITE08PXIB203092PR. 31/10/2008_31/10/2011. 78.970,00 €.
9. Intracellular signaling studies. Mechanisms of interaction between cyclic AMP and calcium in vascular cells. Ministerio de Ciencia y Tecnología (Spain). Reference: RYC2002_10. 01/10/2003_30/09/2008. 6000,00 €.
10. Consolidation 2020 CPG GI_1862 Physiology and Pharmacology of Chronic Diseases. Consellería de Cultura, Educación e Universidade, Xunta de Galicia. 01/01/2020_31/12/2022. 90.000,0 €.
11. Evaluation of the intestinal microbiome of newborns of mothers hospitalized for hypertensive states. Ministerio de la Salud. Gobierno de Brasil. 19.000,00 US\$ (~17207,35 €).
12. Consolidation and structuring 2017. Redes_REGID Galician Network for Research and Development of Medicines. Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria. Ref.ED431D 2017/16. 01/01/2017_31/12/2019. 120.000,00 €.
13. Search for new drugs against pancreatitis. Crowdfunding platform 'Precipita'. Fundación Española para la Ciencia y la Tecnología (FECYT). Reference: 2016_CP109. 2016_2017. 23/09/2016_31/12/2017. 5.974,31 €.
14. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) _ Singular Research Centers 2016. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria. Ref.ED431G/05. 01/01/2016_30/11/2019. 2.482.289,47 €.
15. Consolidación e estruturación. REDES GI_1685 REGID: Galician Network for Research and Development of Medicines. Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria. Reference: R2014/025. 24/06/2014_23/06/2016. 120.000,00 €.
16. Initial development of new curcumin derivatives with potential application in the treatment of neurodegenerative diseases. Consellería de Cultura, Educación e Ordenación Universitaria. Xunta de Galicia. Reference: EM2014/016. 14/05/2014_30/11/2016. 93.000,00 €.
17. Effect of tobacco and its components on the pathogenic, biochemical and molecular mechanisms of chronic pancreatitis: prevention of pancreatic cancer. Fundación Mutua Madrileña. Reference: MMA2010. 2010_2012 12.000,00 €.
18. Consolidation and structuring of the research units of the Galician R+D+i system. Investigation groups. Entidad financiadora: Consellería de Economía Programa xeral de consolidación e estruturación do sistema galego de I +D+i. Reference: 2010_PG430. 01/01/2010_17/12/2010. 16.724,00 €.
19. Consolidation and structuring of the research units of the Galician R+D+i system. Investigation groups. Xunta de Galicia. Consellería de Economía. Programa xeral de consolidación e estruturación do sistema galego de I +D+i. Reference: INCITE09E2R203045ES. 01/01/2009_11/12/2009. 23.892,00 €.
20. Study of the effects of resveratrol isomers on various physiological factors involved in cardiovascular diseases. Xunta de Galicia. Dirección Xeral de I+D. Reference: 08CSA019203PR. 31/10/2008_31/10/2011. 46.352,07 €.
21. Fiberín: Producción de ingredientes alimentarios funcionales a partir de productos tradicionales del medio rural gallego. Fase I: investigación industrial. Tecnomiza S.L. 01/10/2008_30/09/2009. 23.625,00 €.

22. Raisin d'or: producción de vino desalcoholizado enriquecido en polifenoles con efectos beneficiosos sobre la salud humana. Fase I. Investigación industrial. Tecnomiza I+D S.L.16/01/2008_30/09/2010. 69.000 €.
23. Consolidation and structuring of competitive research units (GI_1683). Xunta de Galicia. Consellería de Innovación e Industria. Reference: INCITE08E1R203054ES. 01/01/2008_21/11/2008. 17.066,00 €.
24. Grants for the consolidation of the research units of the Galician research and innovation system: Research Group GI_1683. Xunta de Galicia. Consellería de Innovación e Industria. INCITE07PXI203039ES. 21/12/2007_20/12/2008. 24.379,00 €.
25. Study of the cardioprotective effects of polyphenols analogues of resveratrol and flavonoids. Fondo de Investigaciones Sanitarias (FIS), Ministerio de Sanidad y Consumo. Reference: PI061537. 31/12/2006_30/12/2009. 55.297,00 €.
26. Synthesis and study of the cardiovascular and antithrombotic effects of various derivatives of resveratrol (II). Xunta de Galicia. Consellería de Innovación, Industria e Comercio. PGIDT _ 2002 Biotecnoloxía, Farmacia e Saúde. Reference: PGIDIT05BTF20302PR_1. 05/08/2005_31/10/2008. 100.100,00 €.
27. Synthesis and study of the cardiovascular and antithrombotic effects of various derivatives of resveratrol (I). Xunta de Galicia. Consellería de Innovación, Industria e Comercio. PGIDT _ 2002 Biotecnoloxía, Farmacia e Saúde. Reference: PGIDIT02BTF20301PR. 15/10/2002_14/10/2005. 68.200,00 €.
28. Study of the cardiovascular effects of trans-resveratrol and epigallocatechin gallate in rats. Xunta de Galicia. PGIDT _ PXI (Programa Xeral de Investigación). Reference: PGIDIT02PXIC20305PN. 14/08/2002_13/08/2003. 13.200,00 €.
29. Two distinct, regulated exocytotic pathways in rat pancreatic acinar cells. Biotechnology and Biological Sciences Research Council (BBSRC), United Kingdom. Reference: C111044 1999_2001. 194.538£ (~229.382 €).
30. A study of the possible effects of polyphenolic flavonoids on calcium signalling and nitric oxide production in the vascular endothelium. Institut de Produits de Synthese et d'Extraction Naturelle (IPSEN), Francia. 1997_1999.
31. Pharmacological study as potential antihypertensive agents of various flavones extracted from *Centaurea corubionensis*. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20312B97. 22/07/1997_22/07/2000. 66.652,23 €.
32. Pharmacological study as potential antihypertensive agents of various alkaloids extracted from *Glaucium flavum*. Gobierno de España. Comisión Interministerial de Ciencia y Tecnología (CICYT). Reference: SAF94_0440. 20/05/1994_19/05/1997. 48.080,96 €.
33. New antihypertensive drugs: pharmacological study of various alkaloids of natural origin extracted from *Platycapnos spicata*. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20306B93. 07/04/1994_07/04/1996. 21.035,42 €.
34. Pharmacological study as potential antihypertensive agents of glaucine derivatives of natural and synthetic origin. Gobierno de España. Comisión Interministerial de Ciencia y Tecnología (CICYT). Plan Nacional de I+D. Programa Nacional de Salud y Farmacia. Reference: SAF92_0585. 20/07/1992_19/07/1994. 45.676,91 €.
35. Influence of atheromatosis on the reactivity of the rat aorta. Effects of different modulators of calcium channels on the evolution of the process. Xunta de Galicia Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20312B90. 26/03/1991_26/03/1993. 28.247,56 €.

Memberships

Other Relevant Information